Accept return of EUA-labeled Paxlovid treatment courses
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 13 Oct 2023
- Due
- 31 Dec 2023
- Delivered
- Q4 2023
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“At the end of 2023, Pfizer will accept a non-cash return of any remaining Emergency Use Authorized (EUA)-labeled U.S. government inventory”
What we found
Evidence strength A What the grades mean
Pfizer recorded a non-cash revenue reversal in the fourth quarter of 2023 related to the expected return of EUA-labeled Paxlovid inventory, confirming the commitment to accept these returns was fulfilled.
-
A Pfizer Inc. 10-Q filed 2024-05-08
“we recorded a non-cash revenue reversal of $3.5 billion in the fourth quarter of 2023 related to the expected return of an estimated 6.5 million treatment courses of EUA-labeled U.S. government inventory.” ✓ confirmed on the page
Market reaction: the shares moved +1.7% against the S&P 500 over the three sessions around the disclosure (7 May 2024 to 10 May 2024). What this measures
Checked 5 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Language weakened: firm → expected
- 2 versions
-
Version 1 · original · stated 13 Oct 2023
Deadline 31 Dec 2023 (“at the end of 2023”) · wording firm
-
Version 2 · stated 31 Oct 2023
Deadline 31 Dec 2023 (“in the fourth quarter of 2023”) · target 7.9 million treatment courses · wording expected
“return of an estimated 7.9 million treatment courses of U.S. government EUA-labeled Paxlovid expected in the fourth quarter of 2023”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Transaction other
- Indicative materiality
- Medium rules
- Action
- Accept
- Deliverable
- Return of EUA-labeled Paxlovid treatment courses
- Where
- U.S.
- Language
- Firm (“will”, “on track to”)
- In the company’s control
- High
- Specificity
- High
- Depends on
- Customer
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Pfizer Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-PFE-004738 · Corrections policy